HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist
HeartBeam (NASDAQ: BEAT) has appointed Dr. Lance Myers as Chief AI Scientist to drive innovation in its cardiac care technology. Dr. Myers, formerly Head of Data Science at Verily (Google Life Sciences), will guide AI application to HeartBeam's core technology. The company's vector-based approach combined with AI has shown equivalent performance to a 12-lead ECG and improved detection of atrial flutter over single-lead ECG.
HeartBeam's technology captures heart signals in three dimensions, with its first application being a cable-free, credit card-sized device capable of synthesizing a 12-lead ECG. The system is under FDA review. The company aims to leverage AI for improved diagnostic accuracy and personalized cardiac care, analyzing longitudinal data from patient device usage.
HeartBeam (NASDAQ: BEAT) ha nominato Dr. Lance Myers come Chief AI Scientist per guidare l'innovazione nella tecnologia per la cura cardiaca. Il Dr. Myers, ex Responsabile della Data Science presso Verily (Google Life Sciences), guiderà l'applicazione dell'IA sulla tecnologia principale di HeartBeam. L'approccio basato su vettori combinato con l'IA ha dimostrato prestazioni equivalenti a un ECG a 12 derivazioni e un miglioramento nella rilevazione del flutter atriale rispetto all'ECG a singola derivazione.
La tecnologia di HeartBeam cattura i segnali cardiaci in tre dimensioni, con la sua prima applicazione che consiste in un dispositivo senza fili delle dimensioni di una carta di credito in grado di sintetizzare un ECG a 12 derivazioni. Il sistema è attualmente in revisione da parte della FDA. L'azienda mira a sfruttare l'IA per migliorare l'accuratezza diagnostica e la cura cardiaca personalizzata, analizzando dati longitudinali dall'uso del dispositivo da parte dei pazienti.
HeartBeam (NASDAQ: BEAT) ha nombrado al Dr. Lance Myers como Chief AI Scientist para impulsar la innovación en su tecnología de atención cardíaca. El Dr. Myers, ex Jefe de Ciencia de Datos en Verily (Google Life Sciences), guiará la aplicación de IA a la tecnología central de HeartBeam. El enfoque basado en vectores combinado con IA ha mostrado un rendimiento equivalente a un ECG de 12 derivaciones y una mejor detección de flutter auricular en comparación con el ECG de una sola derivación.
La tecnología de HeartBeam captura señales cardíacas en tres dimensiones, siendo su primera aplicación un dispositivo inalámbrico del tamaño de una tarjeta de crédito capaz de sintetizar un ECG de 12 derivaciones. El sistema está bajo revisión de la FDA. La empresa busca aprovechar la IA para mejorar la precisión diagnóstica y la atención cardíaca personalizada, analizando datos longitudinales del uso del dispositivo por parte de los pacientes.
HeartBeam (NASDAQ: BEAT)는 Dr. Lance Myers를 수석 AI 과학자로 임명하여 심장 관리 기술의 혁신을 이끌고 있습니다. 전 Verily(구글 생명과학) 데이터 과학 책임자였던 Dr. Myers는 HeartBeam의 핵심 기술에 AI 응용을 안내할 것입니다. AI와 결합된 벡터 기반 접근법은 12리드 ECG와 동등한 성능을 보였으며, 단일 리드 ECG에 비해 심방 세동의 탐지를 개선했습니다.
HeartBeam의 기술은 심장 신호를 3차원으로 캡처하며, 첫 번째 응용은 12리드 ECG를 합성할 수 있는 카드 크기의 케이블 없는 장치입니다. 이 시스템은 FDA 심사 중입니다. 회사는 환자 장치 사용에 대한 장기 데이터를 분석하여 개선된 진단 정확도와 개인화된 심장 치료를 위해 AI를 활용하는 것을 목표로 하고 있습니다.
HeartBeam (NASDAQ: BEAT) a nommé Dr. Lance Myers en tant que Chief AI Scientist pour conduire l'innovation dans sa technologie de soins cardiaques. Dr. Myers, ancien responsable de la science des données chez Verily (Google Life Sciences), guidera l'application de l'IA sur la technologie centrale de HeartBeam. L'approche basée sur des vecteurs combinée à l'IA a montré une performance équivalente à celle d'un ECG à 12 dérivations et a amélioré la détection du flutter auriculaire par rapport à un ECG à dérivation unique.
La technologie de HeartBeam capture les signaux cardiaques en trois dimensions, sa première application étant un dispositif sans fil de la taille d'une carte de crédit capable de synthétiser un ECG à 12 dérivations. Le système est en cours d'examen par la FDA. L'entreprise vise à tirer parti de l'IA pour améliorer l'exactitude diagnostique et les soins cardiaques personnalisés, en analysant des données longitudinales provenant de l'utilisation des dispositifs par les patients.
HeartBeam (NASDAQ: BEAT) hat Dr. Lance Myers zum Chief AI Scientist ernannt, um Innovationen in der Herzpflege-Technologie voranzutreiben. Dr. Myers, ehemaliger Leiter der Data Science bei Verily (Google Life Sciences), wird die Anwendung von KI auf die Kerntechnologie von HeartBeam leiten. Der vektorbasierte Ansatz in Kombination mit KI hat eine vergleichbare Leistung wie ein 12-Kanal-EKG gezeigt und die Erkennung von Vorhofflattern im Vergleich zu einem Einzelableitungs-EKG verbessert.
Die Technologie von HeartBeam erfasst Herzsignale in drei Dimensionen, wobei die erste Anwendung ein kabelloses, kreditkartengroßes Gerät ist, das in der Lage ist, ein 12-Kanal-EKG zu synthetisieren. Das System befindet sich im FDA-Überprüfungsverfahren. Das Unternehmen zielt darauf ab, KI für eine verbesserte diagnostische Genauigkeit und personalisierte Herzpflege zu nutzen, indem es longitudinal Daten aus der Nutzung des Geräts durch die Patienten analysiert.
- Appointment of industry leader Dr. Lance Myers as Chief AI Scientist
- HeartBeam AI with vector-based approach showed equivalent performance to 12-lead ECG
- Improved detection of atrial flutter over single-lead ECG
- 13 issued US patents and 4 issued international patents supporting the technology
- FDA review underway for the HeartBeam system
- HeartBeam AI is still under development
- FDA approval for the HeartBeam system is pending
Insights
The appointment of Dr. Lance Myers as Chief AI Scientist at HeartBeam is a significant development for the company's AI strategy. His extensive experience in digital health data analytics and biosensor technologies, particularly from his role at Verily (Google Life Sciences), brings valuable expertise to HeartBeam's AI initiatives.
HeartBeam's core technology, which captures heart signals in three dimensions, has shown promising results when combined with AI. The company claims its deep learning approach, coupled with a vector-based method, has demonstrated performance equivalent to a 12-lead ECG and improved detection of atrial flutter compared to single-lead ECGs.
The potential for AI to analyze longitudinal ECG data from HeartBeam's credit card-sized device could lead to more personalized cardiac care. This approach may offer a significant advancement over traditional 12-lead ECGs, which only provide a snapshot in time.
However, it's important to note that HeartBeam's system is still under FDA review and the AI capabilities are in development. The company's success will depend on regulatory approval and the effective implementation of AI in real-world clinical settings.
HeartBeam's integration of AI into its cardiac monitoring technology represents a promising intersection of healthcare and advanced computing. The company's approach of using a compact, cable-free device capable of synthesizing a 12-lead ECG, combined with AI analysis, could potentially disrupt traditional cardiac monitoring methods.
The company's patent portfolio, consisting of 13 US and 4 international patents, provides a strong foundation for its technological claims. However, the true value of this IP will be realized only if the technology proves effective in clinical applications and gains market acceptance.
Dr. Myers' vision of leveraging AI for diagnostics, screening, predictive analytics and closed-loop patient management is ambitious. If successful, it could significantly enhance the management of cardiac conditions. The concept of using longitudinal data to refine and optimize treatment outcomes aligns with the broader trend of personalized medicine in healthcare.
Investors should monitor HeartBeam's progress in FDA approval processes and the development of its AI capabilities, as these will be critical milestones for the company's future success and potential market impact.
Industry Leader, Former Head of Data Science at Verily (Google Life Sciences) and Globally Respected Authority on Artificial Intelligence (AI) Applications in Biosensor Technologies
Dr. Myers to Drive Innovation and Strategic Growth as HeartBeam Advances and Expands its AI Capabilities
“We’ve made tremendous progress with our deep learning approach with data demonstrating that combining HeartBeam AI with a vector-based approach delivered equivalent performance to a 12-lead ECG and greatly improved detection of atrial flutter over a single-lead ECG,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam. “As we enter the next phase of development, we’re pleased to have an industry leader of Lance’s caliber join our team. His insights and expertise will have an immediate impact as we strive to transform cardiac care by harnessing the power of AI with our data-rich technology.”
HeartBeam’s core technology captures the heart’s electrical signals from three dimensions to provide total heart intelligence. The Company’s first application of the technology is a cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG. The HeartBeam system is currently under review with the FDA and is the foundational 510(k) submission upon which future submissions will be based. The Company has 13 issued US patents and 4 issued international patents supporting the underlying technology.
By leveraging AI to analyze the data-rich signals, the Company believes it will be able to improve diagnostic accuracy and unlock a more personalized approach to cardiac care for patients. As a patient uses the HeartBeam device over time, there will be a series of ECG readings. The Company aims to leverage AI to analyze the data to provide a longitudinal view of the patient’s cardiac status and move beyond today’s 12-lead ECGs, which typically only provide a snapshot in time. HeartBeam AI is currently under development.
“Being appointed as Chief AI Scientist is both an honor and an exciting challenge. The HeartBeam technology, when combined with advanced AI, has tremendous potential to unlock and deliver groundbreaking cardiac management solutions spanning diagnostics, screening, predictive analytics and closed-loop patient management – where detection, intervention and real-time measurement continually refine and optimize treatment outcomes. By leveraging longitudinal trends and increasing user data, we can uncover new insights, pushing the boundaries of AI in cardiac care and bringing transformative advancements to patients,” commented Dr. Myers.
Most recently, Dr. Myers served as AI Advisor to HeartBeam. Previously, he was the Head of Cardiovascular Devices at Verily Life Sciences (formerly Google Life Sciences), where he led a team developing a novel heart failure monitoring solution. Prior to that, he was the Head of Data Science at Verily and built a high-performance AI organization with teams in computational biology, medical device and biosensor algorithms, digital biomarkers, health informatics and digital pathology. He has also held leadership roles at XAI.health, Sentrian, VivoSense, Boston Neurosciences and Vivometrics. He currently serves as a board member for VivoSense and is on the scientific advisory boards of Acorai, XAI.health and Bryte. Dr. Myers received his PhD in Biomedical Engineering from the University of
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The Company holds 13 US and 4 international issued patents related to technology enablement.
For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240924390170/en/
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Media Contact:
media@heartbeam.com
Source: HeartBeam, Inc.
FAQ
What is HeartBeam's (BEAT) new AI-focused appointment?
How does HeartBeam's (BEAT) technology compare to traditional ECGs?
What is the current status of HeartBeam's (BEAT) device with the FDA?
How many patents does HeartBeam (BEAT) have for its technology?
